NurExone Secures Australian IP on Stem Cell Exosome Production

NurExone Biologic has added Australian Patent No. 2020303456 to its international IP portfolio, covering the production of extracellular vesicles from stem cells. Granted by IP Australia on April 23, 2026, and valid until June 10, 2040 (subject to fee maintenance), the patent signals a maturing IP strategy that manufacturing and QA teams at contract development and manufacturing organizations should monitor closely as exosome-based therapies approach commercial-scale production requirements.

The patent is held by Technion Research and Development Foundation Limited and exclusively licensed to NurExone. It follows grants already secured in Israel and the United States, with additional applications under examination in other jurisdictions. For plant heads evaluating cell-derived extracellular vesicle programs, the expanding geographic coverage reflects a deliberate effort to align IP protection with key regulatory and commercial markets, a pattern increasingly relevant as CDMOs assess partnership risk and technology transfer feasibility under GMP frameworks.

NurExone CEO Dr. Lior Shaltiel framed the grant in operational terms: "Consistency is one of the most important value drivers in biomanufacturing," noting the patent supports scalable, reproducible exosome production. The company has also signed a letter of intent with U.S.-based BioXtek to build manufacturing capacity, suggesting near-term pressure on process validation and sterility assurance protocols as the platform moves toward clinical and potentially commercial supply.

In parallel, NurExone's ExoPTEN asset will be featured in a preclinical scientific presentation at ISCEV@Denver on May 2, 2026. Researchers from the Goldschleger Eye Institute at Sheba Medical Center will present electroretinography data as a functional biomarker for optic nerve regeneration in a rat crush model, part of a collaborative preclinical program between NurExone and Sheba Medical Center.

Source: NurExone Biologic Inc. press release via GlobeNewswire, April 27, 2026.